Drug Trial Radar · NCT03390504
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
629
Actual
Start
Mar 23, 2018
Primary completion
Apr 15, 2024
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
Conditions
- Urothelial Cancer
Interventions
ErdafitinibDrug
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
VinflunineDrug
Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
DocetaxelDrug
Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
PembrolizumabDrug
Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Device
FGFRi CTA will be used to determine molecular eligibility.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
Locations
345 sites in 27 countries. Site status is shown where the registry gives one.
Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, Alaska
University of Calif Davis Medical Center
Sacramento, California
St. Helena Hospital - Martin-O'Neil Cancer Center
St. Helena, California
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
University of Miami Sylvester Cancer Center
Miami, Florida
Mid Florida Hematology Oncology
Orange, Florida
Piedmont Cancer Institute
Atlanta, Georgia
Rush University
Chicago, Illinois
Edward Hines Jr V A Hospital
Hines, Illinois
Norton Cancer Institute
Louisville, Kentucky
Maryland Oncology Hematology, PA
Lanham, Maryland
University of Michigan Health System
Ann Arbor, Michigan
VA Sierra Nevada Health Care System
Reno, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Weill Cornell Medical College
New York, New York
Montefiore Medical Center
The Bronx, New York
Levine Cancer Institute, Carolinas HealthCare System
Charlotte, North Carolina
W G Bill Hefner VA Medical Center
Salisbury, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
The Center for Cancer and Blood Disorders
Fort Worth, Texas
Texas Oncology-Memorial City
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology Tyler
Tyler, Texas
INOVA Dwiight &Martha Schar Cancer Institute
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
VA Puget Sound Healthcare System
Seattle, Washington
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
Buenos Aires, Argentina
Centro Oncológico Korben
Buenos Aires, Argentina
CEMIC Saavedra
Buenos Aires, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
Córdoba, Argentina
Centro Urologico Profesor Bengio
Córdoba, Argentina
Hospital Privado de Comunidad
Mar del Plata, Argentina
Centro de Investigacion Pergamino SA
Pergamino, Argentina
Clínica Viedma
Viedma, Argentina
Chris O'Brien Lifehouse
Camperdown, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Australia
St George Hospital
Kogarah, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Frankston Hospital
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Showing 40 of 345 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.